VIII. 510(k) Summary

K01213f

SUBMITTER:

DePuy AcroMed, Inc.

325 Paramount Drive

Raynham, MA 02780

NOV 1 4 2001

CONTACT PERSON:

Karen F. Jurczak

DATE PREPARED:

August 15, 2001

CLASSIFICATION NAME:

Piston Syringe

PROPRIETARY NAME:

Symphony Graft Delivery System

PREDICATE DEVICES:

Symphony Graft Delivery System (K003286, K010320)

INTENDED USE:

The Symphony Graft Delivery System is indicated for the delivery of allograft, autograft, or synthetic bone graft materials to an orthopedic surgical site. In addition, it is designed to facilitate pre-mixing of bone graft materials with I.V. fluids, blood, plasma, platelet rich plasma, bone marrow or other specific blood component(s) as deemed

necessary by the clinical use requirements.

MATERIALS:

Medical grade polycarbonate resin

Medical grade High Density Polyethylene

PERFORMANCE

DATA:

The resins, from which the components of the Symphony Graft Delivery System are manufactured, meet the requirements set forth in the Tripartite Biocompatibility Guidance for Medical Devices. This Guidance includes testing requirements for Pharmacopeia XXII, Class VI as

well as the FDA modified ISO 10993-1 tests for

biocompatibility for human body fluid contact of 30 days or

less.

DESIGN:

The Symphony Graft Delivery System Syringe is designed specifically to collect, mix and deliver bone graft materials to a surgical site. The Graft Chamber component of the Symphony GDS can be provided either empty or pre-filled

with human allograft.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Karen F. Jurczak Regulatory Affairs Associate DePuy AcroMed, Inc. 325 Paramount Drive Raynham, Massachusetts 02767 NOV 1 4 2001

Re: K012738

Trade/Device Name: Symphony Graft Delivery System (GDS)

Regulation Number: 878.4820

Regulation Name: Surgical instrument motors and accessories/attachments

Regulatory Class: I Product Code: GEY Dated: August 15, 2001 Received: August 16, 2001

Dear Ms. Jurczak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Symphony Graft Delivery System
IV. Indications for Use 510(k) Number (if known):
Device Name: Symphony Graft Delivery System
The Symphony Graft Delivery System is indicated for the delivery of allograft, autograft or synthetic bone graft materials to an orthopedic surgical site. In addition, it is designed to facilitate pre-mixing of bone graft materials with I.V. fluids, blood, plasma, platelet rich plasma, bone marrow or other specific blood component(s) as deemed necessary by the clinical use requirements.
(Please do not write below this line - continue on another page if needed)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use: OR Over-The-Counter Use: OR Over-The-Counter
(Per 21 CFR 801.109) (Division Sign-Off) Division of General, Restorative
and Neurological Devices

510(k) Number

K012738